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Abstract
Background: Infliximab (IFX) has proven to be an effective addition to the therapeutic arsenal for
refractory, fistulizing, and steroid dependent Crohn's disease (CD), with efficacy in the induction
and maintenance of clinical remission of CD. Our objective in this study is to report the nationwide,
multicenter experience with IFX induction therapy for CD in Hungary.
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BMC Gastroenterology 2009, 9:66 http://www.biomedcentral.com/1471-230X/9/66Methods: During a 6-year-period, beginning in 2000, a total of 363 CD patients were treated with
IFX as induction therapy (5 mg/kg IFX infusions given at week 0, 2 and 6) at eleven centers in
Hungary in this observational study. Data analysis included patient demographics, important disease
parameters and the outcome of IFX induction therapy.
Results: Three hundred and sixty three patients (183 women and 180 men) were treated with IFX
since 2000. Mean age was 33.5 ± 11.2 years and the mean duration of disease was 6.7 ± 6.1 years.
The population included 114 patients (31.4%) with therapy-refractory CD, 195 patients (53.7%)
with fistulas, 16 patients (4.4%) with both therapy-refractory CD and fistulas, and 26 patients (7.2%)
with steroid dependent CD. Overall response rate was 86.2% (313/363). A higher response rate
was observed in patients with shorter disease duration (p = 0.05, OR:0.54, 95%CI:0.29-0.99) and
concomitant immunosuppressant therapy (p = 0.05, OR: 2.03, 95%CI:0.165-0.596). Concomitant
steroid treatment did not enhance the efficacy of IFX induction therapy. Adverse events included
34 allergic reactions (9.4%), 17 delayed type hypersensitivity (4.7%), 16 infections (4.4%), and 3
malignancies (0.8%).
Conclusion: IFX was safe and effective treatment in this cohort of Hungarian CD patients. Based
on our experience co-administration of immunosuppressant therapy is suggested in patients
receiving IFX induction therapy. However, concomitant steroid treatment did not enhanced the
efficacy of IFX induction therapy.
Background
Infliximab (IFX) is a chimeric monoclonal antibody that
binds soluble and membrane bound tumor necrosis fac-
tor-alpha (TNF-α). Previous studies have demonstrated its
efficacy in refractory, fistulizing, and steroid dependent
Crohn's disease (CD) [1,2]. Furthermore, other studies
have shown its efficacy as maintenance therapy for CD
[3], moreover as induction and maintenance therapy for
ulcerative colitis [4].
In Hungary, IFX has been used in clinical studies since
2000, and has served as an important component of the
therapeutic arsenal for the treatment of CD since 2003.
Financial considerations limit the use of IFX treatment for
CD to eleven Hungarian Gastroenterological Centers
which are licensed for its administration. Initially, IFX was
available only for induction therapy for patients suffering
from fistulizing, therapy resistant, or steroid dependent
CD. However, as clinical evidence demonstrates the effi-
cacy of IFX for maintenance therapy [3], currently IFX is
available for maintenance therapy as well. The objective
of this observational study is to report the nationwide,
multicenter experience with IFX induction therapy for CD
in Hungary.
Methods
This observational study was initiated in 2004, therefore a
portion of the patient data (2000 through 2004) are retro-
spective. Patient data through six years from eleven Hun-
garian Gastroenterological Centers are included in this
analysis. Microsoft® Excel databases were used to compile
and process patient data including demographic charac-
teristics, localization and behaviour of the disease, con-
comitant medication, indication for biological therapy
and outcome of IFX induction therapy were registered ret-
rospectively. The study protocol was reviewed and
approved by the Semmelweis University Regional and
Institutional Committee of Science and Research Ethics.
Patients with Crohn's Disease eligible for this observa-
tional study had 1) single or multiple discharging abdom-
inal and/or perianal fistulas of at least 3-6 months
duration despite conventional immunosuppressant and
antibiotic therapy; 2) therapy refractory/steroid depend-
ent luminal disease. Minority of patients had active lumi-
nal and fistulizing disease as well. Patients who are either
unable to reduce corticosteroids below the equivalent of
prednisolone 10 mg/day within three months of starting
corticosteroids without recurrent active disease, or who
have a relapse within three months of stopping corticos-
teroids were defined as corticosteroid dependent patient.
Corticosteroid refractory disease was defined as active dis-
ease despite prednisolone up to 0.75-1 mg/kg/day over a
period of four weeks defined as steroid refractory. Patients
who not tolerate AZA in a dose at least 1.5 mg/kg body
weight were considered as AZA intolerant. Failure of
immunosupressants (AZA or else) therapy or AZA intoler-
ance was an indication for IFX therapy also.
As induction therapy five mg/kg body weight of inflixi-
mab was administered in a 2 hour infusion at weeks 0, 2
and 6. In fistulizing disease response was defined as a
decrease of 50% or more in the number of discharging fis-
tulas compared to baseline and remission was defined as
absence of any discharging fistulas measured at week 12.
In patients with therapy-refractory or steroid dependentPage 2 of 7
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BMC Gastroenterology 2009, 9:66 http://www.biomedcentral.com/1471-230X/9/66luminal disease the response was defined as a ≥70 points
decrease in CDAI and a CDAI value below 150 was con-
sidered as clinical remission at week 12. The Crohn's Dis-
ease Activity Index (CDAI) was calculated only in cases
with steroid dependent or therapy-refractory luminal dis-
ease.
Infliximab 5 mg/kg body weight was given as mainte-
nance therapy after week 6. Maintenance was given every
8 weeks. The initiation of the maintenance therapy was
based on the assessment of response following the induc-
tion regimen. However, financial restrictions prevented a
significant proportion of patients from receiving mainte-
nance therapy. Conventional induction therapy (1 mg/kg
body weight steroid therapy) was started in case of early
disease relapse in patients with luminal CD. In case of late
relapse (defined as relapse after at least 6 months of remis-
sion) IFX re-induction regimen was administered.
Statistcal methods
Variables were tested for normality using Shapiro Wilk's
W test. T-test with separate variance estimates, ANOVA
with post hoc Scheffe test, χ2-test, and χ2-test with Yates
correction were used to evaluate differences within sub-
groups of IBD patients. The results are presented as means
± SD. Association between response, remission and clini-
cal variables (with variables with a p < 0.2 in univariate
analysis) was also tested by using logistic regression anal-
ysis. A p value of < 0.05 was considered as significant. For
the statistical analysis, SPSS15.0 (SPSS Inc, Chicago, IL)
was used.
Results
During a 6-year-period 363 CD patients were treated with
IFX. The cohort comprised 183 females and 180 males;
the mean age was 33.5 ± 11.2 years and the mean duration
of disease was 6.7 ± 6.1 years at the time of initiation of
induction therapy.
One hundred and ninety five (53.7%) fistulizing, 114
(31.4%) therapy-refractory, and 26 (7.2%) steroid
dependent CD patients were treated. All patients were
naïve to TNFα-inhibitor therapy. Five (0.1%) patients
with metastatic CD and 7 (0.2%) patients with extra-intes-
tinal manifestations were also treated, but these patients
were not available for assessment of response. The details
regarding the specific indications for IFX therapy are sum-
marized in Table 1.
During the observation period 1,532 IFX infusions were
administered. Complete induction regimen was per-
formed in 299 patients (82.3%). Overall response rate
was 86.2% thus 313 patients out of the 363 responded to
the induction therapy. Details regarding the response rates
are shown in Table 1. The overall remission rate was
46.0% (167 out of 363 patients) after IFX induction ther-
apy. Detailed data on remission rates are shown in Table
2.
Among 304 (83.7%) patients treated simultaneously with
immunosuppressants, 268 responded (88.2%), and 36
failed to respond (11.8%). Fifty nine (16.2%) patients did
not receive any concomitant immunosuppressants and
the response rate was lower in these patients respect to
those on concomitant immunosuppressive therapy (73%
vs 88.2%, p < 0.05). Among patients with concomitant
immunosuppressants, azathioprine (AZA) was used most
frequently (78.9%). Other immunosuppressant therapies
included methotrexate (5.9%), and only one patient
(0.3%) was treated with cyclosporine and another with
mycophenolate mofetil (0.3%). Response rate to IFX
induction therapy was higher in patients receiving con-
comitant AZA or methotrexate (88.3% vs. 76.6%, p =
0.014).
During induction therapy co-administration of pre-infu-
sion corticosteroid therapy was applied in 165 patients.
Response rates were similar for patients with or without
concomitant steroid treatment (88.5% vs. 85.8%, respec-
tively, p = NS).
Patients who achieved remission or response after induc-
tion therapy were significantly younger than patients clas-
sified as non-responders (26.8 ± 10.4 years vs. 33.2 ± 11.5
years of age, p < 0.01), furthermore the duration of CD
was shorter (5.9 ± 5.5 years vs. 7.2 ± 4.3 years, p < 0.001).
Abdominal surgery prior to IFX therapy was performed in
25.1% of CD patients. This subset of patients was older in
age (35 ± 10.9 years of age, p = 0.01), and the mean dura-
tion of disease was longer (8.5 ± 6.3 years, p < 0.0001)
compared to the entire group of patients. Among patients
with previous surgical intervention 75% responded to IFX
induction therapy.
Out of 167 patients in remission 136 (81.4%) received
simultaneous immunosuppressive regimen. The majority
of patients in remission receiving concomitant immuno-
suppressants were treated with AZA (132 patients,
97.0%), 4 patients (2.9%) received methotrexate, and
mesalazine or sulphasalazine was used in 128 (93.4%)
and 8 (5.9%) of them respectively.
A logistic regression analysis was performed to test the
association between clinical variables, concomitant med-
ical therapy and remission and response to IFX induction
treatment (Table 3.). Duration (p = 0.05, OR: 0.54,
95%CI: 0.29-0.99) and concomitant steroid therapy (p =
0.027, OR: 0.54, 95%CI: 0.31-0.93) were associated with
remission at week 12 in the same logistic regression anal-
ysis.Page 3 of 7
(page number not for citation purposes)
BMC Gastroenterology 2009, 9:66 http://www.biomedcentral.com/1471-230X/9/66Adverse events during induction treatment were observed
in 78 patients (21.5%, 3.86/100 patient-years). Allergic
reactions were detected in 34 patients (43.6% of all
adverse events, 1.56/100 patient-years) including 4 events
progressing to anaphylactic shock - IFX therapy was
immediately discontinued in these cases. Patients suffer-
ing from mild to moderate allergic reactions were able to
finish the IFX therapy by pre-administering parenteral cor-
ticosteroids. Despite previous severe allergic reactions, in
2 patients successful desensitization was performed with
stepwise diluted IFX and they were subsequently re-chal-
lenged with continuation of their IFX induction therapy.
Delayed type hypersensitivity reactions (DTHR), charac-
terized by muscle pain, fever, joint pain and skin rashes
were observed in 17 patients (0.78/100 patient-years). In
five of these cases the DTHR occurred after the 2nd infu-
sion of IFX induction regimen, and only one patient was
able continue IFX therapy after resolution of the DTHR.
Infections were observed in 16 patients (4.4%, 0.73/100
patient-years) including serious infections in 5 patients
(0.01%, 0.23/100 patient-years) such as two cases of
tuberculosis, two intra-abdominal abscesses, and one
meningeal Listeriosis. The majority of infections (11/16,
68.8%) occurred in patients treated with concomitant
immunosuppressants. No fatal infectious complications
were observed.
In four cases symptoms of gut stenosis developed after IFX
therapy (0.55%, 0.011/100 patient-years), two cases
required surgery.
Three cases of malignant solid tumors were observed
(0.82%, 0.137/100 patient-years). The first case was diag-
nosed on the 2nd week of therapy, and was considered
unrelated to IFX treatment. In this case, an abdominal
abscess was the initial diagnosis because of high fever and
diffuse, sharp abdominal pain. However, the diagnosis of
colon malignancy was confirmed based on histological
evaluation of a tissue sample. In the second case the
malignancy was diagnosed in a patient 5 month after the
start of induction therapy. This patient had severe therapy-
resistant and fistulizing CD with a 15-year disease dura-
Table 1: Indications and response rates of infliximab induction therapy
Indication of IFX therapy Number and rate of disease type Response rate after induction
Therapy-refractory CD 114 (31.4%) 83.3%
By localization
Ileum 10 (8.77%)
Colon 29 (25.4%) 79.3%
Ileo-colonic 46 (40.4%) 87.0%
Ileo-colonic and small bowel 28 (24.6%) 78.6%
Oesophagus 1 (0.9%) 1/1
Therapy-refractory and fistulizing 16 (4.4%) 93.8%
Fistulizing 195 (53.7%) 85.6%
By localization
Perianal 148 (75.9%) 91.2%
Enterocutaneous 24 (12.3%) 87.5%
Enterovaginal 11 (5.6%) 9/11
Other 12 (6.2%) 7/12
Mixed 7 (3.6%) 5/7
Steroid dependent 26 (7.2%) 92.3%
By localization
Ileum 3 (11.5%) 3/3
Colon 4 (15.4%) 4/4
Ileo-colic 19 (73.1%) 17/19
Metastatic 5 (0.1%) Na.
Other 7 (0.2%) Na.
Na = not applicablePage 4 of 7
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Table 2: Remission rate after infliximab induction therapy
Indication of IFX therapy Number and rate of remission
Overall 167 (46%)
Therapy-refractory CD
by localization
45 (39.47%)
Ileum 3/10 (30%)
Colon 7/29 (24.13%)
Ileo-colonic 29/46 (63.04%)
Ileo-colonic and other small bowel 5/28 (17.85%)
Oesophagus 1/1
Therapy-refractory and fistulizing 6 (37.5%)
Fistulizing 95 (48.71%)
Perianal 72/148 (48.64%)
Enterocutaneous 7/24 (29.16%)
Enterovaginal 3/11
Other 4/12
Mixed 6/7
Steroid dependent 15 (57.69%)
Ileum 3/3
Colon 3/4
Ileo-colic 9/19 (47.36%)
Metastatic 5 Na.
Other 1 Na.
Na = not applicable
Table 3: Logistic regression: Predictive factors for response to IFX induction therapy at week 12 in Crohn's disease
Factor Coefficient P value OR 95% CI
Gender 0,070 0.828 - -
Longer disease duration
(≤ 10 years vs. > 10 years)
-1.161 < 0.001 0.349 0.165-0.596
Disease behavior -0,312 0.349 - -
Concomitant AZA/methotrexate use 0.710 0.05 2.03 1.001-4.168
Steroid use -0,438 0.184 - -
The coefficient is equivalent to the natural log of the OR; p value: level of significance;
OR: odds ratio; 95% CI: 95% confidence interval.
BMC Gastroenterology 2009, 9:66 http://www.biomedcentral.com/1471-230X/9/66tion, and was diagnosed with rectal carcinoma resulting in
multiple mesenterial adenocarcinoma metastases. The
patient died a few months after the diagnosis. The third
malignant solid tumor observed in this cohort was a lung
cancer. The patient was diagnosed 4 months after the start
of induction therapy, although chest X-rays obtained prior
to the start of IFX induction therapy did not show any evi-
dence of solid tumor. Initially, the patient was observed
for fever, a bad cough and swelling of lower extremities.
Computer tomography of the chest revealed the tumor,
which was diagnosed histologically as a squamous cell
carcinoma. The overall mortality rate was 0.82% (0.137/
100 patients-years).
Discussion
The results of this observational study of CD patients
treated at eleven Gastroenterology Centers in Hungary
confirm the efficacy of IFX induction therapy reported in
previous investigations [5,6]. Data collection was partially
retrospective which was one of the limitations of the
study. Although, all centers had to have collect some data
regarding their patients because of financial requirement.
These kinds of data were collected in the retrospective and
prospective phase also.
Overall response and remission rates observed in this
study were 86% and 46%, respectively. Notably, the
response rate was higher among younger patients, and in
patients with a shorter duration of CD. Among patients
with perianal and enterovaginal fistulas a high response
rate were observed after IFX therapy, which is in concord-
ance with previously reported data [7,8].
Higher response and remission rates after induction IFX
therapy were observed in patients receiving concomitant
therapy with immunosuppressants. In Hungary AZA is the
most commonly used immunosuppressant. Given that
there are little data on co-administration of other immu-
nosuppressants would improve the therapeutic benefits of
IFX in CD [9], we conclude that AZA would be an appro-
priate first choice [10]. In the present study early response
was higher in patients with concomitant AZA, while
remission rates at week 12 were higher in patients receiv-
ing steroids. The combined effect of the two drugs was not
investigated. In addition shorter disease duration was
associated with a higher response and remission rate in a
logistic regression analysis. Recent results in SONIC study
confirms our experiences, but only in AZA naïve patients
[11]. In contrast, disease location or behavior were not
independent predictors for early response or remission.
Based on our experience IFX therapy was effective therapy
for patients with metastatic CD or intractable skin mani-
festations. In some cases we achieved significant improve-
ment of the symptoms, in accordance with results
observed by others [12].
Based on the further data collection a single induction IFX
therapy may maintain the remission in a relatively high
proportion of patients with luminal disease [13].
The most common adverse events were allergic reactions.
In our Gastroenterology Centers, steroid pre-medication
was not routinely administered at the initiation of induc-
tion therapy. However, in case of allergic reactions re-
treatment was attempted applying parenteral corticoster-
oid administration and slower infusion rate of IFX accord-
ing to recommendations of Sandborn et al. [14]. Farrel et
al. [15] found lower anti-infliximab antibody (ATI) for-
mation after intravenous hydrocortisone pre-medication.
Based on these findings and our experience, regular ster-
oid pre-medication remains questionable when regular
immunosuppressant therapy is administered in parallel.
Two patients despite severe allergic reaction were further
treated with IFX based on the instructions of Duburgue et
al [16]. Applying this method we were able to continue
maintenance therapy in one patient, however in the sec-
ond patient, the second dilution series lead to an allergic
reaction.
The diagnosis of delayed type hypersensitivity reaction
must be considered in case of fever, muscle or joint pain
and rash appear several weeks after IFX therapy [17].
Increasing the dose of immunosuppressant and introduc-
ing corticosteroid pre-medication was effective and safe in
one of our patients experiencing a delayed hypersensitiv-
ity reaction [18].
Five patients experienced serious infection and all were
treated with broad spectrum antibiotics. One of these
patients with meningitis caused by Listeria monocytogenes
had to be further treated in intensive care unit.
In two patients tuberculosis was diagnosed (0.55%, 0.09/
100-patient years). Based on our experience the observed
tuberculosis incidence is higher among patients treated
with IFX and other immuosupressive co-medication than
the reported average 0.02% tuberculosis incidence in
Hungary in 2005 [19]. Tuberculin skin tests were applied
in all patients before initiating IFX therapy. Results of the
tests were hardly interpretable because the immunization
of a newborn is obligatory in Hungary. It was important
to take into consideration the social circumstances and
family history of the patients in this situation.
General incidence of infections was also reported to be
higher in IFX treated patients [20], but IFX treatment itself
did not predispose to infections [21]. We conclude that
performing a tuberculin test and chest x-ray should be
mandatory in all situations before anti-TNF therapy. Fur-
thermore, regular x-ray examination is suggested for IFX-
treated patients in geographic areas with high prevalencePage 6 of 7
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calculated from the database of the TREAT registry [20].
Conclusion
IFX was safe and effective as induction therapy in this
cohort of Hungarian CD patients. Based on our experi-
ence in 11 Gastroenterology Centers in Hungary, co-
administration of immunosuppressant therapy and
shorter disease duration was associated with significantly
improved response/remission rates suggested in patients
receiving IFX induction therapy.
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